A costly therapeutic dilemma in tophaceous gout: Is etanercept or rasburicase preferable? [5] (multiple letters)

Annals of the Rheumatic Diseases

Volumn 64, Issue 3, 2005, Pages 516-

  Reinders, M K ^a   Van Roon, E N ^a   Brouwers, J R B J ^a   Jansen, T L Th A ^a   Tausche, A K ^b   Schroder H E ^b  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; ETANERCEPT; PROBENECID; RASBURICASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; URIC ACID;

DRUG COST; DRUG EFFICACY; GOUT; HUMAN; KIDNEY FUNCTION; LETTER; PRIORITY JOURNAL; TOPHACEOUS GOUT; URIC ACID BLOOD LEVEL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, GOUTY; HUMANS; IMMUNOGLOBULIN G; INFANT, NEWBORN; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TREATMENT OUTCOME; URATE OXIDASE;

EID: 20044387594     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.017087corr1     Document Type: Letter

References (0)